Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF V600
BRAF V600 - Associated Disease
- melanoma
- Source Database
- CIViC Evidence
- Description
- Phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655. Partial response was observed in 4 of 17 patients with BRAF V600 mutated melanoma. 2 patients with prior vemurafenib treatment progressed under treatment.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/994
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/17
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Melanoma
- Evidence Direction
- Supports
- Drug
- MEK Inhibitor RO4987655
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24947927
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| MEK Inhibitor RO4987655 | Sensitivity | true |